ROCKWELL MEDICAL, INC

Rockwell Medical, Inc. specializes in the manufacturing of pharmaceutical preparations, with a focused expertise in renal therapeutics and specialty drug formulations. Their core capabilities center on the production of active pharmaceutical ingredients and finished dosage forms, particularly for chronic kidney disease management, including dialysis-related therapies such as renal-specific electrolyte pellets and phosphate binders. The company demonstrates technical proficiency in GMP-compliant manufacturing processes, sterile and non-sterile compounding, and formulation stability validation under FDA regulatory frameworks. Their specialization in nephrology-focused products distinguishes them in the niche market of renal care pharmaceuticals, where precision dosing, bioavailability control, and patient-specific delivery systems are critical. Rockwell Medical’s primary government partner is the Department of Veterans Affairs, where they supply specialized pharmaceuticals used in VA renal care programs, particularly for veterans requiring long-term dialysis support. Their relationship with the VA reflects a trusted vendor status in delivering mission-critical medications that support chronic condition management within the VA’s integrated healthcare network. The company operates primarily under NAICS 325412, which encompasses the manufacturing of pharmaceutical preparations, including oral solids, injectables, and specialty formulations. Their market positioning is defined by a narrow but deep focus on nephrology therapeutics, serving a specialized segment of the federal healthcare supply chain where product consistency and regulatory compliance are paramount. Rockwell Medical, Inc. is structured as a small business (2L) headquartered in Wixom, Michigan. While no formal government certifications are listed, their operations adhere to FDA cGMP standards and quality systems required for federal pharmaceutical supply. Their geographic presence is centered in Michigan, with a targeted government market footprint focused on federal healthcare delivery systems requiring specialized renal pharmaceuticals.